Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 32

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

225

HTML

1188

Figures (1-9)

173

Tables (1-1)

195

Sum=1781

Aug 28, 2006 (publication date) through Jul 25, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Aug 28, 2006; 12(32): 5160-5167
Published online Aug 28, 2006. doi: 10.3748/wjg.v12.i32.5160

Full Size Figure Download Figure

Figure 9 Antiproliferative effects of erlotinib plus AG1024. A: HepG2; B: Huh-7.

Citation: Huether A, Höpfner M, Sutter AP, Baradari V, Schuppan D, Scherübl H. Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 2006; 12(32): 5160-5167
URL: https://www.wjgnet.com/1007-9327/full/v12/i32/5160.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i32.5160